Most next-generation obesity peptides are variations on a familiar theme: combine GLP-1 with GIP, glucagon or another metabolic target, and see whether the result improves on treatments already available. Boehringer Ingelheim’s BI 3034701 takes a different route. It is designed to activate GLP-1 and GIP receptors alongside a third target, the neuropeptide Y receptor type 2, or NPY2. That last receptor is associated with the brain’s regulation of hunger and food intake, and it has a history that stretches back to a landmark appetite experiment in 2002.
The molecule is now being tested in a 344-person Phase 2 obesity trial. The study is designed to measure weight loss across six active treatment groups and placebo over 42 weeks. But no Phase 2 efficacy results have been published, and the central scientific question remains unanswered: does the additional NPY2 activity provide any advantage beyond GLP-1 and GIP?
This is a pipeline explainer, not a results story. The experiment is underway. The evidence needed to judge it is still coming.
Why Neuropeptide Y2 Is an Unusual Third Receptor
Neuropeptide Y is one of the nervous system’s important appetite-regulating signals. It acts through several related receptors, which do not all produce the same effects. The Y2 receptor became particularly interesting to obesity researchers because of its relationship with another hormone, peptide YY, or PYY.
After a meal, the intestine releases PYY, and one of its circulating forms, PYY3-36, activates the Y2 receptor. In 2002, Rachel Batterham and colleagues published a study in Nature showing that PYY3-36 reduced food intake in rodents. Its effect was absent in mice lacking the Y2 receptor, supporting that receptor’s role in appetite regulation. The researchers also administered PYY3-36 to human volunteers and reported reduced appetite and food intake.
The experiment established an important biological possibility: a signal originating in the gut could influence appetite-related pathways in the brain. But identifying a pathway is not the same as making a successful medicine from it.
Subsequent research has not always reproduced the early PYY3-36 findings consistently, particularly in animal experiments. More than two decades after the original discovery, Y2-targeted approaches have not become established obesity treatments.
BI 3034701 is Boehringer’s attempt to bring that biology into a molecule that also activates two better-established metabolic drug targets. Gubra, the Danish company that developed the candidate in cooperation with Boehringer, describes NPY2 activity as a way to influence hunger and food intake while GLP-1 and GIP activity provides complementary metabolic and appetite effects.
The important distinction is that the GLP-1/GIP combination has demonstrated clinical effectiveness through medicines such as tirzepatide. The added benefit of NPY2 in this triple agonist has not been established.
Two receptors have clinical validation as a combination. The third is what Boehringer is betting on.
What BI 3034701’s 344-Person Phase 2 Trial Will Actually Measure
On July 16, 2026, Boehringer Ingelheim and Gubra announced the start of Phase 2 development for BI 3034701. Gubra said the milestone triggered a payment of €10 million from its partner, which is responsible for the drug’s further clinical development and global commercialization.
The companies’ announcements offered limited trial details, but the public registration supplies a much clearer picture.
The study, registered as NCT07662122, is a randomized, double-blind, placebo-controlled Phase 2 dose-finding trial. Its updated registry information lists 344 participants across seven groups. Six groups receive different doses of BI 3034701, while one receives placebo. Treatment is administered by subcutaneous injection over 42 weeks.
The primary endpoint is percentage change in body weight from baseline at week 42. Secondary measures include the proportion of participants achieving at least 5%, 10%, 15% or 20% weight loss, along with changes in waist circumference, blood pressure and other measurements.
Eligible participants are adults aged 18 to 74 with obesity, or overweight accompanied by at least one weight-related complication. People with type 2 diabetes are excluded. All participants also receive lifestyle counseling.
The study began on June 30, 2026, before the companies’ July announcement. The October registry update lists it as active but not recruiting, with completion expected around mid-2027. That is an estimate, not a confirmed results-release date.
This design can tell investigators whether different doses produce meaningful weight loss relative to placebo, and how tolerability changes as dosing increases. It cannot, on its own, isolate the specific contribution of NPY2 activity. There is no separate GLP-1/GIP-only comparator in the registered study.
Phase 2 can establish whether the molecule works. Proving why it works is a different challenge.
What Phase 1 Has Shown, and What Remains Unpublished
BI 3034701 has already completed an earlier randomized Phase 1 study, registered as NCT06352437. That trial enrolled 125 healthy volunteers and adults with overweight or obesity and concluded in October 2025.
Its primary focus was safety and tolerability, including treatment-emergent adverse events considered drug-related by investigators. The study also examined how different doses behaved in the body.
On its public pipeline page, Gubra says the Phase 1 program demonstrated a favorable safety and tolerability profile and encouraging weight loss. Those are sponsor-reported qualitative conclusions. Detailed numerical results sufficient to independently evaluate the magnitude of weight loss, the dose-response relationship and adverse-event differences have not been posted in the reviewed trial registry.
That distinction matters. A company can reasonably decide that early data justify further testing without having demonstrated a clinically meaningful advantage over an existing treatment. Moving into Phase 2 is evidence of continued development, not proof of differentiation.
Readers should be particularly cautious about interpreting early tolerability claims. Larger and longer studies can reveal problems that short Phase 1 trials were not designed or powered to detect.
A favorable early profile is a reason to test a drug. It is not the test’s final answer.
Boehringer Already Stopped One Standalone NPY2 Obesity Program
There is a detail in the partnership’s history that makes BI 3034701 especially interesting.
On October 31, 2024, Gubra announced that Boehringer had discontinued development of another NPY2 receptor agonist, BI 1820237, for obesity. Unlike BI 3034701, that candidate targeted NPY2 without the same GLP-1/GIP triple-agonist combination.
Gubra said at the time that Boehringer had provided no further explanation for its decision. The company also emphasized that the broader partnership remained intact, including the triple agonist then undergoing Phase 1 development.
Gubra’s current pipeline description says BI 1820237 had shown no unexpected safety concerns in Phase 1 and had demonstrated effects on energy intake and gastric emptying. Its obesity program nevertheless stopped, with possible development outside obesity being explored.
The discontinuation does not establish that NPY2 agonism is ineffective. Without the full rationale and clinical data, it would be inappropriate to claim that efficacy, tolerability or commercial considerations specifically caused the decision.
But it makes the strategy clearer. Boehringer has already explored NPY2 activation independently and is now testing it alongside GLP-1 and GIP activity. Whether the combination offers an advantage is precisely the question the next development stage must help resolve.
The receptor is not a new discovery. The question is whether combining it with established incretin targets changes the result.
How BI 3034701 Differs From Retatrutide and Survodutide
The word “triple agonist” can make several substantially different drug-development strategies sound interchangeable.
Eli Lilly’s retatrutide activates GLP-1, GIP and glucagon receptors. The glucagon component is intended to influence energy expenditure and liver metabolism alongside the appetite and metabolic actions of GLP-1 and GIP. Grey Pepper previously explained this approach in our review of retatrutide’s triple-agonist science.
Boehringer’s own survodutide uses a related but two-receptor strategy, combining GLP-1 and glucagon activity. It has progressed into Phase 3 development, where both weight-loss efficacy and tolerability have been closely examined. Our coverage of survodutide’s Phase 3 results explains why discontinuation rates matter alongside headline weight-loss percentages.
BI 3034701 instead combines GLP-1 and GIP with NPY2. Its experimental third component focuses more directly on appetite-signaling biology rather than adding glucagon receptor activation.
That could prove useful. Different receptor pathways might offer complementary appetite control or make different dose combinations possible. But neither possibility has been demonstrated for BI 3034701.
There are also scientific reasons to remain cautious. Appetite pathways overlap, and activating additional receptors does not necessarily produce additive benefits. Different levels of activity at each receptor may change efficacy and tolerability in ways that cannot be predicted reliably from the receptor list alone.
Cross-trial comparisons will be another temptation. Even if BI 3034701 eventually produces substantial weight loss, comparing its results with retatrutide or tirzepatide studies conducted in different populations, with different doses and treatment durations, will not establish superiority.
Three receptor targets do not automatically mean three complementary clinical benefits.
What Would Count as Success for BI 3034701?
The first requirement is straightforward: a convincing reduction in body weight compared with placebo, accompanied by a dose-response pattern and an acceptable safety profile over the 42-week treatment period.
The second is more demanding. Boehringer must eventually establish why BI 3034701 deserves a place in a market already populated by effective GLP-1-based treatments. That might mean greater weight loss, better tolerability for a comparable effect, a useful difference in appetite control or another clinically relevant advantage.
The registered Phase 2 trial can contribute to that assessment, but its placebo-controlled design cannot definitively attribute any improvement to the NPY2 component. Mechanistic evidence, an appropriate active comparator or later head-to-head research may be needed to distinguish the value of the third receptor from the already established effects of GLP-1 and GIP activation.
Gubra has described BI 3034701’s progression as an important validation of its peptide-discovery platform. From a business perspective, reaching Phase 2 and triggering a €10 million milestone are meaningful achievements. From a scientific perspective, they do not yet tell us whether the drug is better than existing options.
The next important event is therefore not another announcement that the molecule has three targets. It is the release of interpretable human efficacy and safety data.
BI 3034701 is one of the more distinctive experimental approaches in the current obesity pipeline because it draws on appetite biology outside the familiar glucagon-based triple-agonist model. Its potential is genuine enough to warrant a substantial Phase 2 study. Its added clinical value remains unproven.
Nearly a quarter-century after researchers linked PYY3-36 and the Y2 receptor to food intake, Boehringer is testing whether that old biological insight can improve a modern obesity medicine.
The receptor is established biology. The therapeutic advantage is still a hypothesis.
Sources
- ClinicalTrials.gov. A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight. NCT07662122, Phase 2 registration and updates.
- Boehringer Ingelheim. Boehringer Ingelheim Strengthens Obesity Pipeline as BI 3034701 Enters Phase II Development, July 16, 2026.
- Gubra. Boehringer Ingelheim Initiates Phase 2 Clinical Trial of Gubra-Originated Triple Receptor Agonist, July 16, 2026.
- ClinicalTrials.gov. A Study to Test How Well Different Doses of BI 3034701 Are Tolerated. NCT06352437, completed Phase 1 study.
- Gubra. Research and Development Pipeline. Sponsor-reported BI 3034701 and BI 1820237 clinical summaries, accessed November 9, 2026.
- Gubra. Discontinuation of NPY2R Development in Obesity With Boehringer Ingelheim, October 31, 2024.
- Batterham RL et al. Gut Hormone PYY3-36 Physiologically Inhibits Food Intake. Nature, 2002;418:650-654.
- Tschöp M et al. Physiology: Does Gut Hormone PYY3-36 Decrease Food Intake in Rodents? Nature, 2004. Independent replication concerns.
